Standout Papers

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayes... 2022 2026 2023 2024168
  1. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection (2022)
    Sahil Khanna, Maha Assi et al. Drugs

Immediate Impact

39 standout
Sub-graph 1 of 14

Citing Papers

Polysaccharides with antioxidant activity: Extraction, beneficial roles, biological mechanisms, structure-function relationships, and future perspectives: A review
2025 Standout
Antimicrobial peptide biological activity, delivery systems and clinical translation status and challenges
2025 Standout
2 intermediate papers

Works of Joe Marion being referenced

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
2022 Standout

Author Peers

Author Last Decade Papers Cites
Joe Marion 2 145 21 78 75 4 170
Marie Hocquart 135 39 90 94 6 191
Sashidhar Sagi 169 68 114 67 5 203
Bradley A. Schmidt 151 39 77 190 6 272
Karrie Derenski 122 36 42 179 3 287
Francesco Pecora 66 35 47 29 7 276
Ashton Harper 48 27 66 137 7 289
Teri Crumb 201 52 87 175 10 294
Fabio Del Zompo 119 46 66 130 10 289
Lindsay Potts 81 33 71 49 5 182
Dagmara I. Moscoso 90 56 44 114 9 258

All Works

Loading papers...

Rankless by CCL
2026